Hannah Poppen, PharmD (@PoppenPharmD) reviews guideline recommendations for management of blood cholesterol, describes the risks and benefits associated with adjunct non-statin therapy and identifies patient-specific characteristics in which PCSK9 inhibitor therapy should be considered.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.